Ke Liu
Chief Development Officer Marengo Therapeutics
Seminars
Wednesday 20th May 2026
Activating T-Cells Through Novel TCR-Based Platforms to Overcome Resistance in Solid Tumors
9:30 am
- Introducing the first-in-class STAR platform that selectively activates T-cells via the variable beta chain
- Demonstrating feasibility and safety of this novel mechanism with encouraging preliminary clinical data
- Achieving pan-tumor activity across seven solid tumor types, and HLA-agnostic TCR activation to broaden patient access and redefine therapeutic strategies
